These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 8958606)

  • 21. Safety issues in heparin and protamine administration for extracorporeal circulation.
    Jobes DR
    J Cardiothorac Vasc Anesth; 1998 Apr; 12(2 Suppl 1):17-20. PubMed ID: 9583571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Measurement of activated clotting time during cardiopulmonary bypass in infective endocarditis patients].
    Jiang L; Yu JF
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2007 Feb; 32(1):167-9. PubMed ID: 17344611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content.
    Chawla LS; Moore G; Seneff MG
    Obes Surg; 2004 May; 14(5):695-8. PubMed ID: 15186641
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Low-molecular-weight heparin: an anticoagulation therapy option.
    Mege J
    Pa Med; 1999 Dec; 102(12):16, 18. PubMed ID: 10641527
    [No Abstract]   [Full Text] [Related]  

  • 25. Heparin and low molecular weight heparin in thrombosis and beyond.
    Mousa SA
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1181-6. PubMed ID: 12211411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emergency reversal of heparin overdose in a neurosurgical patient guided by thromboelastography.
    Figueiredo S; Vigué B; Benhamou D; Duranteau J
    Br J Anaesth; 2013 Aug; 111(2):303-4. PubMed ID: 23858079
    [No Abstract]   [Full Text] [Related]  

  • 27. Anticoagulation and anticoagulation reversal with cardiac surgery involving cardiopulmonary bypass: an update.
    Despotis GJ; Joist JH
    J Cardiothorac Vasc Anesth; 1999 Aug; 13(4 Suppl 1):18-29; discussion 36-7. PubMed ID: 10468245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Filter run time in CVVH: pre- versus post-dilution and nadroparin versus regional heparin-protamine anticoagulation.
    van der Voort PH; Gerritsen RT; Kuiper MA; Egbers PH; Kingma WP; Boerma EC
    Blood Purif; 2005; 23(3):175-80. PubMed ID: 15711037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Thrombosis prophylaxis with heparins in intensive care patients].
    Greinacher A; Janssen D
    Anasthesiol Intensivmed Notfallmed Schmerzther; 2005 Mar; 40(3):156-63. PubMed ID: 15770559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anticoagulation with heparin during cardiac catheterization and its reversal by protamine.
    Dehmer GJ; Haagen D; Malloy CR; Schmitz JM
    Cathet Cardiovasc Diagn; 1987; 13(1):16-21. PubMed ID: 3815512
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Protamine sulfate: crouching clot or hidden hemorrhage?
    Nielsen VG; Malayaman SN
    Anesth Analg; 2010 Sep; 111(3):593-4. PubMed ID: 20733163
    [No Abstract]   [Full Text] [Related]  

  • 32. [Immediate protamine sulphate allergy in an insulin-treated diabetic patient].
    Petäys T; Kiistala R; Mäkinen-Kiljunen S
    Duodecim; 1999; 115(5):517-20. PubMed ID: 11830901
    [No Abstract]   [Full Text] [Related]  

  • 33. Postoperative anticoagulation in vascular surgery: part 1. A retrospective comparison of clinical outcomes for unfractionated heparin versus low-molecular-weight heparin.
    Gramse CA; Hingorani A; Ascher E
    J Vasc Nurs; 2001 Jun; 19(2):42-9; quiz 50-1. PubMed ID: 11395717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In-laboratory removal of femoral sheath following protamine administration in patients having intracoronary stent implantation.
    Pan M; Suárez de Lezo J; Medina A; Romero M; Hernández E; Segura J; Melian F; Wangüemert F; Landin M; Benítez F; Amat M; Velasco F; Torres A
    Am J Cardiol; 1997 Nov; 80(10):1336-8. PubMed ID: 9388109
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical considerations for the anesthesiologist whose patient is on anticoagulant therapy.
    Ellison N; Ominsky AJ
    Anesthesiology; 1973 Sep; 39(3):328-36. PubMed ID: 4580632
    [No Abstract]   [Full Text] [Related]  

  • 36. Antibodies against heparin-protamine complexes: Effect and clinical relevance.
    Beckerman Z; Cohen O
    J Thorac Cardiovasc Surg; 2015 Oct; 150(4):974-5. PubMed ID: 26320779
    [No Abstract]   [Full Text] [Related]  

  • 37. Current use of low molecular weight heparins.
    Donayre CE
    Semin Vasc Surg; 1996 Dec; 9(4):362-71. PubMed ID: 8958613
    [No Abstract]   [Full Text] [Related]  

  • 38. [Protamin-sulfate in cardiac surgery: between Scilla and Haribda].
    Charnaia MA; Morozova IuA; Gladysheva VG
    Khirurgiia (Mosk); 2006; (12):45-9. PubMed ID: 17419491
    [No Abstract]   [Full Text] [Related]  

  • 39. Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin.
    Spinler SA; Wittkowsky AK; Nutescu EA; Smythe MA
    Ann Pharmacother; 2005; 39(7-8):1275-85. PubMed ID: 15956240
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DVT prevention. Low-molecular-weight heparin is a viable option.
    Benton L
    Am J Nurs; 2000 Feb; 100(2):84. PubMed ID: 10712165
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.